MetaCap

Sera Prognostics Inc. Class A (SERA)

NASDAQ: SERAHealth CareMedical SpecialitiesUSD

1.81-0.08 (-4.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SERA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$71.98M
EPS (TTM)
-$0.67
52-week range
1.56 – 3.85
Day range
1.80 – 1.87
Volume / Avg
94.60K / 27.84K
Beta
—

52-week range

$1.56$3.85

SERA stock today

On Nov 20, SERA ended the session at $1.81, shedding $0.08 (4.23%), versus the S&P 500's 3.70% decline. Volume was 3.4x the average at 94.60K shares, a sign of unusually heavy trading. Shares are 53.0% below their 52-week high of $3.85, set on Jan 8, 2026 and 16.0% above the 52-week low of $1.56, near the bottom of the past year's range.

SERA is down 38.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.0%. Sera Prognostics has posted a net loss over the last twelve months (EPS of -$0.67), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sera Prognostics

Company profile

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.

Industry
Medical Specialities
CEO
Ms. Zhenya Lindgardt M.B.A.
Headquarters
Salt Lake City, UT
Employees
71
IPO year
2021
Website
sera.com

Financial highlights

Full financials

In fiscal 2025, Sera Prognostics generated $81,000 in revenue, up 5.2% from fiscal 2024. Sera Prognostics reported a net loss of $31.9 million, compared with a loss of $32.9 million a year earlier. Gross margin was -102.5% (down from -6.5%) and operating margin -45066.7%.

Sera Prognostics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$81.00K$77.00K$306.00K$268.00K$82.00K
Growth+5.19%-74.84%+14.18%+226.83%+228.00%
Net income$-31.93M$-32.90M$-36.24M$-44.19M$-35.01M
EPS (diluted)$-0.67$-0.99$-1.16$-1.43$-2.33

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$5.50+203.87%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $6.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.16 vs $-0.14
Surprise
-14.29%

SERA news

All SERA news

Sera Prognostics peers

Health Care sector
SERA peer companies
CompanyPrice% ChgMarket capCompare
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs SERA
XGNExagen Inc.3.61-5.00%$92.10Mvs SERA
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs SERA
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs SERA
AMSAmerican Shared Hospital Services1.00-4.76%$6.67Mvs SERA
BNRBurning Rock Biotech Limited ADR13.24-0.60%$139.63Mvs SERA
ACONAclarion Inc.1.22-13.92%$3.52Mvs SERA
ADVBAdvanced Biomed Inc.1.65-5.71%$2.73Mvs SERA

Indexes, lists and sector

Sera Prognostics stock FAQ

What is Sera Prognostics's stock price today?

SERA last traded at $1.81 as of Nov 20, 4:00 PM EST, down 4.23% on the day. Prices are delayed at least 15 minutes.

Who is Sera Prognostics's CEO?

Ms. Zhenya Lindgardt M.B.A. is the chief executive officer of Sera Prognostics Inc. Class A, which has about 71 employees.

What is the SERA 52-week high?

The 52-week high for SERA is $3.85 and the 52-week low is $1.56. The stock is currently 53.0% below its high.

Compare SERA